Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AR099625A1 - Anticuerpos de il-21 - Google Patents
[go: Go Back, main page]

AR099625A1 - Anticuerpos de il-21 - Google Patents

Anticuerpos de il-21

Info

Publication number
AR099625A1
AR099625A1 ARP150100643A ARP150100643A AR099625A1 AR 099625 A1 AR099625 A1 AR 099625A1 AR P150100643 A ARP150100643 A AR P150100643A AR P150100643 A ARP150100643 A AR P150100643A AR 099625 A1 AR099625 A1 AR 099625A1
Authority
AR
Argentina
Prior art keywords
seq
antibody
sequence
chains
mammalian cell
Prior art date
Application number
ARP150100643A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR099625A1 publication Critical patent/AR099625A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicación 1: Un anticuerpo que se une a IL-21 humana caracterizado porque comprende una región variable de cadena pesada (HCVR) y una región variable de cadena ligera (LCVR) en donde la LCVR comprende la SEQ ID Nº 7 en la CDRL1, la SEQ ID Nº 8 en la CDRL2 y la SEQ ID Nº 9 en la CDRL3 y en donde la HCVR comprende la SEQ ID Nº 10 en la CDRH1, la SEQ ID Nº 11 en CDRH2 y la SEQ ID Nº 12 en la CDRH3. Reivindicación 5: Una molécula de ADN caracterizada. porque comprende un polinucleótido que codifica la cadena pesada de anticuerpo cuya secuencia de aminoácido es la secuencia de la SEQ ID Nº 3. Reivindicación 11: Una célula de mamífero transformada con la molécula de ADN de conformidad con la reivindicación 5 o reivindicación 6 y la molécula de ADN de conformidad con la reivindicación 7 o reivindicación 9, caracterizada porque la célula de mamífero transformada es capaz de expresar un anticuerpo que comprenden dos cadenas pesadas de anticuerpo y dos cadenas ligeras de inmunoglobulina, en las cuales la secuencia amino de cada una de las dos cadenas pesadas es la secuencia de la SEQ ID Nº 3 y la secuencia de aminoácido de cada una de las dos cadenas ligeras es la secuencia de la SEQ ID Nº 4. Reivindicación 13: Un proceso para producir un anticuerpo, en el cual el anticuerpo comprende dos cadenas pesadas de anticuerpo y dos cadenas ligeras de inmunoglobulina, en las cuales la secuencia amino de cada una de las dos cadenas pesadas es la secuencia de la SEQ ID Nº 3 y la secuencia de aminoácido de cada una de las dos cadenas ligeras es la secuencia de la SEQ ID Nº 4, y caracterizado porque comprende: a) cultivar la célula de mamífero de la reivindicación 11 o la célula de mamífero de la reivindicación 12 bajo condiciones de manera que el anticuerpo es expresado, y b) recuperar el anticuerpo expresado. Reivindicación 15: Un método para tratar una condición autoinmune en un paciente, caracterizado porque comprende administrar una dosis efectiva del anticuerpo de conformidad con cualquiera de las reivindicaciones 1 a 4 ó 14 al paciente. Reivindicación 24: Una composición farmacéutica caracterizada porque comprende el anticuerpo de conformidad con cualquiera de las reivindicaciones 1, 2, ó 12 y un excipiente farmacéuticamente aceptable.
ARP150100643A 2014-03-21 2015-03-04 Anticuerpos de il-21 AR099625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
AR099625A1 true AR099625A1 (es) 2016-08-03

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100643A AR099625A1 (es) 2014-03-21 2015-03-04 Anticuerpos de il-21

Country Status (24)

Country Link
US (1) US9394362B2 (es)
EP (1) EP3119806B1 (es)
JP (2) JP6053989B2 (es)
KR (1) KR101859857B1 (es)
CN (1) CN106061999B (es)
AP (1) AP2016009450A0 (es)
AR (1) AR099625A1 (es)
AU (1) AU2015231777B2 (es)
BR (1) BR112016019176A2 (es)
CA (1) CA2939543C (es)
CL (1) CL2016002281A1 (es)
EA (1) EA033335B1 (es)
EC (1) ECSP16075416A (es)
ES (1) ES2774422T3 (es)
IL (1) IL246909A0 (es)
MA (1) MA39342B2 (es)
MX (1) MX2016012120A (es)
MY (1) MY177915A (es)
NZ (1) NZ722518A (es)
PE (1) PE20161221A1 (es)
PH (1) PH12016501820A1 (es)
SG (1) SG11201606705QA (es)
TW (1) TWI646105B (es)
WO (1) WO2015142637A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CA3018792C (en) * 2016-03-31 2023-03-28 Eli Lilly And Company Il-21 antibodies and uses thereof
US11554131B2 (en) * 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
US20220289822A1 (en) 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
AU2022309238A1 (en) * 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024525611A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2007111714A2 (en) * 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
ME03057B (me) * 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
US7883700B2 (en) * 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
WO2012098113A1 (en) 2011-01-17 2012-07-26 Novo Nordisk A/S Il-21 ligands
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体

Also Published As

Publication number Publication date
KR101859857B1 (ko) 2018-05-18
CL2016002281A1 (es) 2017-06-23
PH12016501820A1 (en) 2016-11-07
MX2016012120A (es) 2016-12-09
US20150266954A1 (en) 2015-09-24
MA39342B2 (fr) 2020-03-31
EP3119806A1 (en) 2017-01-25
CA2939543C (en) 2018-01-16
MY177915A (en) 2020-09-25
PE20161221A1 (es) 2016-11-12
JP2016520088A (ja) 2016-07-11
JP6053989B2 (ja) 2017-01-11
JP6373944B2 (ja) 2018-08-15
TWI646105B (zh) 2019-01-01
BR112016019176A2 (pt) 2017-10-10
ES2774422T3 (es) 2020-07-21
NZ722518A (en) 2017-12-22
EP3119806A4 (en) 2017-11-01
AP2016009450A0 (en) 2016-09-30
EP3119806B1 (en) 2020-01-01
CN106061999A (zh) 2016-10-26
TW201623330A (zh) 2016-07-01
WO2015142637A1 (en) 2015-09-24
CN106061999B (zh) 2020-07-31
US9394362B2 (en) 2016-07-19
EA033335B1 (ru) 2019-09-30
CA2939543A1 (en) 2015-09-24
AU2015231777A1 (en) 2016-08-18
KR20160124166A (ko) 2016-10-26
JP2017093435A (ja) 2017-06-01
EA201691521A1 (ru) 2017-02-28
SG11201606705QA (en) 2016-09-29
IL246909A0 (en) 2016-09-29
AU2015231777B2 (en) 2017-08-03
ECSP16075416A (es) 2018-05-31
MA39342A1 (fr) 2018-03-30

Similar Documents

Publication Publication Date Title
AR099625A1 (es) Anticuerpos de il-21
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
JP2020500538A5 (es)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR105654A1 (es) Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
RU2019118359A (ru) Антитело к cd73 человека
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
AR111203A1 (es) Inmunoconjugados
AR101875A1 (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20170687A1 (es) Proteinas de enlace a cd127
AR109715A1 (es) Anticuerpos anti-cd27
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
FI3922645T3 (fi) Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja
AR086579A1 (es) Proteinas de union a antigeno
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
PE20180120A1 (es) Proteinas de union a icos
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения

Legal Events

Date Code Title Description
FB Suspension of granting procedure